Leonard Calabrese, DO

Leonard Calabrese, DO

Professor of Medicine 
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University 
R.J. Fasenmyer Chair of Clinical Immunology 
Vice Chairman Department of Rheumatic and Immunologic Diseases 
Orthopaedic and Rheumatologic Institute 
Cleveland Clinic Cleveland, OH 

Related Videos

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar-- INFLIXIMAB-DYYB or others--makes good pharmacoeconomic and clinical sense? Video

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar-- INFLIXIMAB-DYYB or others--makes good pharmacoeconomic and clinical sense?

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar— INFLIXIMAB-DYYB or others—makes good pharmacoeconomic and clinical sense, as opposed to using the reference brand product, ...

Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions? Video

Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions?

Why would specialists want to use biosimilars in their practice? Can you discuss how rheumatologists and pharmacists should make important cost reduction-based clinical decisions when selecting anti-TNF biologics, based on primary differences ...

Once analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings? Video

Once analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings?

Once robust analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings for patients and healthcare institutions?

After physicochemical criteria are met, what kind of clinical trials, with what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars? Video

After physicochemical criteria are met, what kind of clinical trials, with what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars?

After physicochemical criteria are met, what kind of clinical trials, with precisely what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars, and for what range of indications can such approvals be made?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Video

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Can you differentiate based on the specific steps of the approval process, evaluation, clinical trials required, ...

Can you discuss study design, rationale, results, and implications of recent trials focused on anti-TNF biosimilars in the setting of RA, AS, and related conditions? Video

Can you discuss study design, rationale, results, and implications of recent trials focused on anti-TNF biosimilars in the setting of RA, AS, and related conditions?

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence — i.e. clinical trials — focused on the safety and efficacy of approved biosimilar therapies, such as INFLIXIMAB-DYYB ...

What do current ACR guidelines recommend as far as sequencing therapy in patients who have had an insufficient response to methotrexate? Video

What do current ACR guidelines recommend as far as sequencing therapy in patients who have had an insufficient response to methotrexate?

What do current ACR guidelines recommend as far as sequencing therapy in patients who have had an insufficient response to methotrexate?

What biomarkers and clinical findings are most useful for guiding therapy in RA? Video

What biomarkers and clinical findings are most useful for guiding therapy in RA?

What biomarkers and clinical findings are most useful for guiding therapy in RA?

What is the evidence for early, aggressive therapy with biologics in RA? Video

What is the evidence for early, aggressive therapy with biologics in RA?

What is the evidence for early, aggressive therapy with biologics in RA?